RxDoctor Payments Data

Suresh Prabhu, MD

Internal Medicine · Las Vegas, NVNPI 1730111436

Payments from drug & device makers

$8,575in general payments, 2019–2025

Across 423 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Astellas Pharma US Inc$836
  • Johnson & Johnson$692
  • AbbVie$655
  • Novo Nordisk$515
  • Lilly USA, LLC$464
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$8,09294%
  • Education$4826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,575 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$332,747
Medicare patients
791
Services billed
3,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$192,601
OzempicSemaglutide88$106,940
MounjaroTirzepatide66$89,076
FarxigaDapagliflozin Propanediol58$66,787
JardianceEmpagliflozin41$55,409
XareltoRivaroxaban26$36,892
JanuviaSitagliptin Phosphate23$33,853
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$20,775
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$9,916
Tresiba Flextouch U-100Insulin Degludec16$9,230
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen383$8,851
PremarinEstrogens, Conjugated11$6,411
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen204$5,880
Atorvastatin Calcium722$5,587
SymbicortBudesonide/Formoterol Fumarate20$5,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$271$199,013151 claims
Novo NordiskOzempic$515$106,94088 claims
Lilly USA, LLCMounjaro$464$89,07666 claims
AstraZenecaFarxiga, Symbicort$1,317$72,00178 claims
Boehringer IngelheimJardiance$187$55,40941 claims
Johnson & JohnsonXarelto$692$36,89226 claims
MerckJanuvia$157$33,85323 claims
GSKTrelegy Ellipta$268$20,77528 claims
AbbVieSynthroid$655$3,23151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →